These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 6658372)
1. Characterization of the molecular forms of immunoreactive parathyroid hormone in primary hyperparathyroidism and in hyperparathyroidism due to renal failure. Gautvik KM; Gautvik VT; Halvorsen JF Scand J Clin Lab Invest; 1983 Nov; 43(7):553-64. PubMed ID: 6658372 [TBL] [Abstract][Full Text] [Related]
2. Parathyroid hormone: radioimmunoassay and clinical interpretation. Hawker CD Ann Clin Lab Sci; 1975; 5(5):383-98. PubMed ID: 1180481 [TBL] [Abstract][Full Text] [Related]
3. Development of sequence specific radioimmunoassay of human parathyroid hormone and its use in the diagnosis of hyperparathyroidism. Gautvik KM; Teig V; Halvorsen JF; Arnesen E; Myhre L; Heimann P; Tollman R Scand J Clin Lab Invest; 1979 Sep; 39(5):469-78. PubMed ID: 574982 [TBL] [Abstract][Full Text] [Related]
4. Immunoheterogeneity of parathyroid hormone in venous effluent serum from hyperfunctioning parathyroid glands. Flueck JA; Di Bella FP; Edis AJ; Kehrwald JM; Arnaud CD J Clin Invest; 1977 Dec; 60(6):1367-75. PubMed ID: 915003 [TBL] [Abstract][Full Text] [Related]
5. [Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism]. Lo Giudice C; Cascone C; Manente P; Gasparoni P; De Luca M; Rota G; Conte N Minerva Med; 1982 Dec; 73(48):3425-8. PubMed ID: 7177469 [TBL] [Abstract][Full Text] [Related]
6. The influence of parathyroid hormone and its fragments on results from midregion and C-terminal specific radioimmunoassays. Kübler N; Krause U; Wagner PK; Beyer J; Rothmund M Exp Clin Endocrinol; 1987 Mar; 89(1):61-9. PubMed ID: 3595732 [TBL] [Abstract][Full Text] [Related]
7. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy. Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547 [TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
9. Peripheral metabolism of parathyroid hormone in patients with primary hyperparathyroidism as judged by immunological and biological studies. Gautvik KM; Gordeladze JO; Moxheim E; Gautvik VT Eur Surg Res; 1984; 16 Suppl 2():41-54. PubMed ID: 6723731 [TBL] [Abstract][Full Text] [Related]
10. Circulating molecular forms of parathyroid hormone in primary and secondary hyperparathyroidism. Brandão CM; Kasamatsu TS; Oliveira MA; Vieira JG Braz J Med Biol Res; 1989; 22(8):963-5. PubMed ID: 2633848 [TBL] [Abstract][Full Text] [Related]
11. Immunoassays for the detection of parathyroid hormone. Jüppner H; Potts JT J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782 [TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone: before and after parathyroidectomy. Duh QY; Arnaud CD; Levin KE; Clark OH Surgery; 1986 Dec; 100(6):1021-31. PubMed ID: 3787459 [TBL] [Abstract][Full Text] [Related]
13. Immunological evidences for the presence of small late carboxylterminal fragment(s) of human parathyroid hormone (PTH) in circulation in man. D'Amour P; Labelle F; Wolde-Giorghis R; Hamel L J Immunoassay; 1989; 10(2-3):191-205. PubMed ID: 2745718 [TBL] [Abstract][Full Text] [Related]
14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis. Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251 [TBL] [Abstract][Full Text] [Related]
15. Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. Riggs BL; Arnaud CD; Reynolds JC; Smith LH J Clin Invest; 1971 Oct; 50(10):2079-83. PubMed ID: 4330004 [TBL] [Abstract][Full Text] [Related]
16. Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. Henderson JE; Shustik C; Kremer R; Rabbani SA; Hendy GN; Goltzman D J Bone Miner Res; 1990 Feb; 5(2):105-13. PubMed ID: 2316398 [TBL] [Abstract][Full Text] [Related]
17. Comparison of C-terminal and N-terminal PTH in secondary hyperparathyroidism in renal failure. Hortling L; Puutula-Räsänen L; Fyhrquist F Scand J Urol Nephrol Suppl; 1985; 90():51-4. PubMed ID: 3868028 [TBL] [Abstract][Full Text] [Related]
18. Immunoreactive forms of circulating parathyroid hormone in primary and ectopic hyperparathyroidism. Benson RC; Riggs BL; Pickard BM; Arnaud CD J Clin Invest; 1974 Jul; 54(1):175-81. PubMed ID: 4834887 [TBL] [Abstract][Full Text] [Related]
19. Measurement of parathyroid hormone. Endres DB; Villanueva R; Sharp CF; Singer FR Endocrinol Metab Clin North Am; 1989 Sep; 18(3):611-29. PubMed ID: 2673765 [TBL] [Abstract][Full Text] [Related]